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Abstract
The amino acid arginine is a well-known growth hormone (GH) stimulator and GH is an important modulator of linear growth. The aim of
the present study was to investigate the effect of dietary arginine on growth velocity in children between 7 and 13 years of age. Data
from the Copenhagen School Child Intervention Study during 2001–2 (baseline), and at 3-year and 7-year follow-up, were used. Arginine
intake was estimated via a 7 d precoded food diary at baseline and 3-year follow-up. Data were analysed in a multilevel structure in which
children were embedded within schools. Random intercept and slopes were defined to estimate the association between arginine intake
and growth velocity, including the following covariates: sex; age; baseline height; energy intake; puberty stage at 7-year follow-up and
intervention/control group. The association between arginine intake and growth velocity was significant for the third and fourth quintile
of arginine intake (2·5–2·8 and 2·8–3·2 g/d, respectively) compared with the first quintile (,2·2 g/d) (P for trend¼0·04). Protein intake
(excluding arginine) was significantly associated with growth velocity; however, the association was weaker than the association between
arginine intake and growth velocity (P for trend¼0·14). The results of the present study suggest a dose-dependent physiological role of
habitual protein intake, and specifically arginine intake, on linear growth in normally growing children. However, since the study was
designed in healthy children, we cannot firmly conclude whether arginine supplementation represents a relevant clinical strategy. Further
research is needed to investigate whether dietary arginine may represent a nutritional strategy potentially advantageous for the prevention
and treatment of short stature.
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Children with a height of 2 SD below the mean for age and sex
in the general population are defined as having a short stature
and are referred to paediatric endocrinology(1). In about 20 %
of the children with a short stature, a medical explanation for
the poor linear growth will be found(1,2). The other 80 % of
these children remain without a definitive diagnosis and are
labelled as having idiopathic short stature (ISS). ISS is defined
as a condition in which the height of an individual is more
than 2 SD below the corresponding mean height for a given
age, sex and population group, without evidence of systemic,
endocrine, nutritional or chromosomal abnormalities(1,2).
Although the process of linear growth is not entirely under-
stood, it is well known that the somatotropic axis play a key
role in this(3). The somatotropic axis originates in the hypo-
thalamus region and in the pituitary gland, situated right
beneath the hypothalamus. Through the central release of
growth hormone (GH), a peripheral production of insulin-like
growth factor 1 (IGF-1) is stimulated. IGF-1 receptors are
found in proliferating bone chondrocytes, and IGF-1 itself
stimulates the synthesis of collagen(4). From epidemiological
studies it is known that the somatotropic axis is associated
with linear growth in infancy, childhood and puberty. Increased
IGF-1 concentration and subsequently an increased growth vel-
ocity determine the growth curve of each individual child(5).
To increase linear growth in children having ISS, the effect
of GH therapy has been studied extensively. A meta-analysis
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using three randomised controlled trials has shown that the
mean adult height was 21·5 SD score for GH-treated children
with ISS and 22·3 SD score for untreated children with ISS.
The adult height achieved by those in the treated group
significantly exceeded that of the controls, with a mean differ-
ence of 0·65 SD score (about 4 cm)(1). The mean duration of
therapy was 5·4 (SD 1·5) years(1). The cost of height gain
attributable to treatment in children with ISS is about
$10 000–20 000/cm(6). At the current time, there is a study
demonstrating improved quality of life and better psychologi-
cal health due to GH/IGF-1 treatment, particularly in children
with GH deficiency(7). However, the benefits of treatment
should be balanced with the high cost and unknown side
effects of these therapies(2). Consequently, in several
countries, treatment of ISS by GH or IGF-1 treatment is not
paid by insurance(8).
As an alternative to stimulate linear growth by injections of
GH/IGF-1, it is possible to stimulate GH release, and hence
growth physiologically. Physiological factors influencing
GH release and growth include sleep(9), exercise(10) and
diet(11,12). Indeed, from 1982, intravenous arginine adminis-
tration has been clinically used as a method to assess the
responsiveness of the GH secretory system, for example,
when GH deficiency is suspected(13). GH concentration can
increase 20-fold after an intravenous arginine bolus
(0·5 g/kg)(13,14). Additionally, a single oral bolus of arginine
has been found to increase GH concentration 2–4·5-fold in
adults(15,16).
There is evidence that increased arginine intake increases
the GH/IGF-1 release. However, the direct association bet-
ween habitual dietary arginine intake and linear growth is
not well documented. The present study therefore examines
the influence of diet, and, in particular, the habitual intake
of arginine on growth, while also defining the amount of
arginine intake needed for optimal growth in pre-pubertal
children. Optimal growth in the present study is defined as
the maximum growth velocity.
Methods
Population and design
The data were derived from the Copenhagen School Child
Intervention Study (CoSCIS). The CoSCIS aimed to examine
the impact of a doubling of the lessons in physical education
and health education for children in terms of physical and
mental health, motor function and well-being(17). All children
(n 1024) in all eighteen preschool classes in two suburbs of
Copenhagen (Ballerup and Taarnby) were invited to parti-
cipate in the CoSCIS. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects/patients
were approved by the ethical committee at the University
of Copenhagen (reference KA00011gm). Written informed
consent from parents or guardians was required for inclusion.
The intervention consisted of standard physical education
classes used within the Danish school curriculum, with the
volume increased to the equivalent of four school classes
per week (180 min/week) delivered as two weekly classes.
The control group continued to receive the usual two classes
per week (90 min/week). In the Danish school curriculum,
physical education classes take place every week throughout
the whole school year from August to June, and participation
is mandatory for every child. The city council of Ballerup
decided in 1999 that the intervention should be carried out
in all schools in the community from preschool (6–7 years)
to the third grade (9–10 years). Hence, children from Ballerup
served as the non-randomised intervention group and chil-
dren from Taarnby as the control group. Taarnby was selected
because the community, by comparison of socio-economic
status (SES) and other community statistics, was similar to
Ballerup.
Baseline measurements were performed from December
2001 until June 2002 in children at 6–7 years of age. Follow-
up measurements took place from September 2004 until May
2005 in children at 9–10 years of age (3-year follow-up) and
from September 2008 until December 2008 in children at
13–14 years of age (7-year follow-up). For the 7-year
follow-up, informed consent from children and parents or
guardians was sought again, as this measurement was not
planned in the first proposal.
Data collection
Demographic variables. Demographic data, such as sex and
age, were recorded in the school registry system.
Anthropometric variables. Height at baseline and follow-
ups was measured with a portable Harpenden (UK) stadi-
ometer to the nearest 1 mm in stockinet feet, with the child
standing upright against the stadiometer. Growth velocity
(in cm/year) was calculated as follows: (height at 7-year
follow-up 2 height at baseline)/years between 7-year
follow-up and baseline. Body weight was measured using
an electronic scale (Seca 882; Medical Scales) with the subjects
lightly dressed to the nearest 0·1 kg. All measurements were
performed during school time by experienced scientists. Con-
trol measurements did not display systematic differences
between the scientists.
Dietary information. Dietary information was collected in
May 2002 (baseline) and May 2005 (3-year follow-up). Parents
recorded the dietary intake of their child for seven consecutive
days in booklets with precoded fixed answer possibilities sup-
plemented with a possibility for open answers. This booklet
for dietary recording has been developed and used in nation-
wide dietary surveys since 1995(18). The eighteen-page pre-
coded food diary had lists of 277 food items, chronologically
divided in sections for breakfast, lunch, dinner and in-
between snacks. The design of the diary was similar to a
cross-table with food listed on the left and portion sizes
across the top. Food amounts in the diary were presented in
household units (e.g. glasses, pieces or tablespoons) or as por-
tions estimated from photographs. Along with the food diary,
each participant received a photographic booklet that con-
tained thirteen series of colour photographs, each with four
different photographs ranging from small to large portion
sizes. Participants indicated an eating event by filling in how
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many units they had eaten of each food item in the specific
time span. Intakes of foods as well as energy, protein and
specific amino acids (i.e. arginine intake) were calculated
using the General Intake Estimation System, developed by
the Danish Institute for Food and Veterinary Research in
2005 with use of the food database from the National Food
Institute in Denmark(19). Corrections for losses in cooking
were made when calculating nutrient contents.
Dietary information of children who were ill during the diet-
ary reporting at baseline or follow-up was excluded, as well as
dietary information of subjects who had reported their dietary
intake less than 6 d.
The mean intakes of arginine in g/d from baseline and
the 3-year follow-up examinations were calculated ((intake
of arginine at baseline þ intake of arginine at 3-year
follow-up)/2) and used in the present study as the main deter-
minant. The mean energy and protein intakes from baseline
and the 3-year follow-up were used in the present study as
potential confounders.
Puberty development. Pubertal stage was assessed from a
scale of pictures according to Tanner at 3-year and 7-year
follow-up. Girls were staged according to breast development
(b1–b5). The category b1 means no development of breasts
and b5 means full/finished development of breasts. For
boys, measures of genital development (g1–g5) were used.
The category g1 means that the growth and development
of the genitals has not begun, and g5 means fully grown
and mature development of the genitals. The children were
asked to rate their stage of sexual maturity by comparison
with Tanner’s photographs and drawings. The girls did that
together with a female laboratory technician and the boys
together with a male staff member. This was done to respect
the children’s privacy after a careful explanation of the pro-
cedures and purpose, which also was provided to the parents
who were invited to participate in the assessment.
Information from the parents (parental height and
socio-economic status). At baseline, height of both parents
and information about SES were assessed by questionnaires.
The classification of SES was based on information about
the education of the mother in the household, since previous
studies have suggested that health-related risk factors con-
sidered in the CoSCIS are more strongly associated with
the SES of the mother rather than that of the father(20–22).
The education level of the mother was divided into three
categories: (1) #10 years elementary school, (2) high school
or short non-university programmes less than 3 years,
(3) college or university degree over 3 years.
Statistical analysis
Descriptive data are presented as means and standard
deviations for continuous variables and as proportions for
categorical variables.
Growth velocity was normally distributed, according to
histograms and the Kolmogorov–Smirnov/Shapiro–Wilk test.
There were equal variances among the residuals and there
was no autocorrelation present in the residuals, according to
Levene’s test and the Durbin–Watson test.
Subjects with incomplete information on height or arginine
intake were excluded. Missing values of potential confounders
were imputed by means (continuous variables) or medians
(categorical variables) (,10 % of cases for all confounders).
No different results were found when analyses were per-
formed with and without imputed data.
Data were analysed in a multilevel structure in which
children (level 1) were embedded within schools (level 2).
Arginine intake was converted into quintiles and treated as
the categorical variable. The relationship between arginine
intake and growth velocity showed non-significant variance
in intercepts and slopes across the participants in schools.
The association between arginine intake and growth
velocity was estimated, including the following covariates:
sex; age; baseline height and weight; mean energy intake;
puberty stage at the 7-year follow-up; SES; height of the
mother; height of the father; a dummy variable for group
(intervention, 1; control, 0). There was no multicollinearity
in the variables (variance inflation factor; VIF , 3·6).
To obtain the final model, we used a manual stepwise back-
ward selection procedure. Covariates that changed all of the
regression coefficients of arginine quintiles by less than 10 %
were one by one deleted from the model. The following cov-
ariates were left in the final model: sex; age; baseline height;
energy intake; puberty; group. In a subsequent model, we
added dietary protein (excluding arginine, quintiles) as a cov-
ariate in the final model. Furthermore, the association
between dietary protein (excluding arginine) and growth vel-
ocity was estimated, adjusted for sex, age, baseline height,
energy intake, puberty and group. The P value for trend
was calculated by using the median of each quintile of dietary
arginine or protein as a continuous variable in the linear
regression analysis.
In order to determine whether specific combinations of cov-
ariates were associated with growth velocity, the effects were
tested using interaction terms. The following combinations
were separately added to the final model: ‘arginine£ group’,
‘arginine £ sex’ and ‘arginine £ puberty’. None of these inter-
action terms was significant.
All analyses were conducted with the SPSS statistical
software package version 16.0 for Windows (SPSS, Inc.).
P values ,0·05 were considered as statistically significant.
Results
Fig. 1 presents a flow chart of the subject inclusion. A total
of 686 Caucasian children (67 %) aged 6·7 (SD 0·4) years
(range 5·6–8·2) years agreed to participate; children included
218 boys and 185 girls from Ballerup and 141 boys and
142 girls from Taarnby. At 3 years later, the children were
retested. Of these children, fifty-one had withdrawn their
consent to participate, twenty-eight had moved away from
the two districts and eleven did not attend the testing, leaving
596 children to participate in the 3-year follow-up exami-
nation. Again, 3 years later, the children were retested. Of
these, 101 children did not give their consent to partici-
pate, thirty had moved away from the two districts and
thirty-three did not attend the testing, leaving 432 children
Dietary arginine and linear growth 1033
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://doi.org/10.1017/S0007114512002942
Downloaded from https:/www.cambridge.org/core. Open University Library, on 29 Jan 2017 at 15:33:48, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
participating in the 7-year follow-up examination. Incomplete
information at baseline or follow-up on height (n 4) or argi-
nine intake (n 167) was excluded from the present analysis,
leaving 261 children for data analysis.
The characteristics of the children, grouped by year and
sex are shown in Table 1. Energy intake, protein intake and
arginine intake were lower in girls than in boys.
Furthermore, the baseline characteristics (i.e. baseline sex,
age, height, weight, parental height and SES) of the included
children in the analysis were compared with the baseline
characteristics of the total database (including all missing
values) (Table 2). No differences in these baseline character-
istics were found.
Table 3 presents the crude and adjusted association
between mean arginine intake and growth velocity in children
from 7 to 13 years of age. The crude, unadjusted, model
showed no statistically significant association between argi-
nine intake and growth velocity. After adjustment for confoun-
ders (sex, age, baseline height, energy intake, puberty and
group), significant associations between arginine intake and
growth velocity were apparent (P for trend¼0·04). The associ-
ation between arginine intake and growth velocity was signifi-
cant at the third and fourth quintile of arginine intake (2·5–2·8
and 2·8–3·2 g/d, respectively) compared with the first quintile
(,2·2 g/d). No difference on growth velocity was found
between the first and fifth quintile of arginine intake
(Table 3; Fig. 2). The maximal mean difference in growth
velocity was found between the first and fourth quintile
(0·33 (SD 0·14) cm/year; P¼0·02).
When we added dietary protein (excluding arginine) (g/d)
to the final model as an additional covariate, the significant
associations between arginine intake and growth velocity
were no longer statistically significant (Table 3).
When we studied the associations between dietary protein
minus arginine (g/d) and growth velocity, a significant differ-
ence was found for the third quintile of protein minus arginine
intake (65·0–71·6 g/d) compared with the first quintile of
protein minus arginine intake (,58·1 g/d). The maximal
mean difference in growth velocity was 0·27 (SD 0·13) cm/year
(P¼0·04; Table 3; Fig. 2). The test for trend between protein
intake and growth velocity was not statistically significant
(P¼0·14).
Discussion
The aim of the present study was to investigate the association
between dietary amino acid arginine and growth velocity, and,
more specifically, to estimate the amount of arginine intake
CoSCIS
Forty-six classes in eighteen schools
1024 children
Intervention group
Twenty-seven classes in ten
schools 534 children
Baseline
403 children
Complete data
(arginine intake at BA and
FU1 and height at BA and FU2)
109 children
FU1
242 children
Baseline
283 children
Control group
Nineteen classes in eight schools
489 children No informed consent –121
children
Not Caucasian –
ten children 
FU1
354 children
FU2
256 children
FU2
176 children
Complete data
(arginine intake at BA and
FU1 and height at BA and FU2)
152 children
In total
261 children
-Moved (n 20)
-Did not attend the
 testing (n 8)
-Did not want to participate
in follow-up (n 21)
-Moved (n 20)
-Did not attend the
 testing (n 22)
-Did not want to participate
in follow-up (n 56)
Missing complete food
report at baseline or FU1
(n 101)
Missing height
measurement (n 3)
No informed consent –198
children
Not Caucasian –
eight children
-Moved (n 8)
-Did not attend the
 testing (n 3)
-Did not want to participate
 in follow-up (n 30)
-Moved (n 10)
-Did not attend the
 testing (n 11)
-Did not want to participate
in follow-up (n 45) 
-Missing complete food
 report at baseline or FU1
 (n 66)
-Missing height
 measurement (n 1)
2001/2002
(6–7 years)
2004–5
(9–10 years)
2008
(13–14 years)
Fig. 1. Flow diagram of inclusion in the Copenhagen School Child Intervention Study (CoSCIS) and in the present study. BA, baseline; FU1, follow-up 1; FU2,
follow-up 2.
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needed for optimal growth in children aged 7–13 years. The
results indicated that a habitual high mean arginine intake
was associated with a higher growth velocity after adjustment
for sex, age, baseline height, mean energy intake (kJ/d), pub-
erty stage and group (intervention/control). Children with an
arginine intake between 2·8 and 3·2 g/d grew 0·33 cm/year
faster compared with children with an arginine intake lower
than 2·2 g/d. This is a remarkable finding in a group of healthy
Danish children, considering that these children had no indi-
cation of malnutrition and their protein intake (70 g/d), and
consequently arginine intake, was several-fold the intake
level believed to satisfy physiological needs (0·95 g/kg body
weight)(23,24). The present results are in line with a previous
study in rats on the association between dietary arginine and
linear growth(25). However, to our knowledge, the present
study is the first to demonstrate a dose–response effect
between arginine intake and growth velocity, and to define
a value for arginine intake associated with maximal linear
growth, i.e. an intake of 2·8–3·2 g arginine/d for a maximal
growth velocity.
Although there was a statistically significant positive associ-
ation (P for trend) between arginine intake and growth, the
highest quintile of arginine intake was characterised by a
lower growth rate than quintiles 3 and 4 (Table 3; Fig. 2).
This would be consistent with an optimal intake level of
arginine equal to quintiles 3 and 4, i.e. between 2·5 and
3·2 g/d. Further research on this issue is warranted.
The association between arginine intake and growth vel-
ocity became non-significant after adding dietary protein
(without arginine) as a covariate. In Western, well-nourished
societies, the majority of dietary protein is of animal origin
(dairy products, meat and fish), resulting in only limited vari-
ation in both quantity and quality of protein and amino acids
among children in the present study(26).
As dietary arginine and protein (without arginine) are highly
correlated (r 0·8 in the present study), it is not unexpected that
the effect of arginine on linear growth disappeared when we
Table 1. Descriptives of children who participated in the present study
(Mean values and standard deviations or percentages)
Boys Girls
n Mean SD n Mean SD
Background of parents
SES 1/2/3 (%)† 123 31/37/32 132 26/36/38
Height of mother (cm) 114 169 27 132 169 26
Height of father (cm) 114 182 36 132 182 37
Baseline
Age (years) 123 6·8 0·3 138 6·7 0·4
Anthropometrics
Height (cm) 123 124·1 4·4 138 122·2* 5·0
Weight (kg) 123 24·4 3·0 138 23·8 3·6
Dietary intake
Energy intake (MJ/d) 123 8·8 1·7 138 8·0* 1·4
Energy intake (kJ/kg BW) 123 370 80 138 340* 90
Protein intake (g/d) 123 75 17 138 66* 14
Arginine intake (g/d) 123 3·0 0·8 138 2·6* 0·6
Follow-up 1
Age (years) 123 9·6 0·4 138 9·5 0·4
Anthropometrics
Height (cm) 123 140·4 5·3 138 138·9 6·6
Weight (kg) 123 33·6 5·3 138 32·8 6·0
Dietary intake
Energy intake (MJ/d) 123 8·9 1·8 138 7·9* 1·6
Energy intake (kJ/kg BW) 123 272 69 138 248* 66
Protein intake (g/d) 123 74 18 138 65* 13
Arginine intake (g/d) 123 3·0 0·8 138 2·6* 0·6
Puberty stage 1/2/3/4/5 (%)‡ 116 98/2/0/0/0 135 58*/38*/4*/0/0
Follow-up 2
Age (years) 123 13·4 0·4 138 13·3 0·3
Anthropometrics
Height (cm) 123 164·1 8·0 138 162·3 6·2
Weight (kg) 123 51·6 9·8 138 51·1 8·8
Puberty stage 1/2/3/4/5 (%)‡ 120 2/9/49/34/6 132 7/7/25/55/6
SES, socio-economic status of the mother; BW, body weight.
* Mean values or percentages were significantly different from those of the boys (P,0·05).
† SES: 1, #10 years elementary school; 2, high school or short non-university programmes under 3 years; 3, college or university
degree over 3 years.
‡ Puberty stage according to Tanner’s stages. Girls are staged according to breast development (b1–b5). The category b1 means no
development of breasts and b5 means full/finished development of breasts. For boys, measures of genital development (g1–g5) are
used. The category g1 means that the growth and development of the genitals has not begun, and g5 means fully grown and mature
development of the genitals.
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adjusted for protein intake (without arginine). Therefore, due
to the observational design of the present study, we cannot
conclude from the present data that arginine is the single
amino acid associated with linear growth. Nevertheless, the
association between total protein minus arginine and growth
velocity was weaker than the association between dietary argi-
nine and growth velocity. In addition, the P value for trend
was not significant for total protein minus arginine, suggesting
a stronger relationship for arginine than for total protein.
The association between dietary protein and linear growth
has been observed in several human studies. Indeed, other
observational studies have shown positive associations
between protein intake and linear growth among 2·5- and
10-year-old children, after adjustment for sex and body
weight(27,28). Other studies have also supported the notion
that protein is associated with linear growth. A study on the
effects of macrobiotic diets on linear growth in infants and
children until 10 years of age has shown that linear growth
was reduced in children on a macrobiotic diet compared
with children on an omnivorous diet, and that linear growth
was positively associated with the protein content of the
diet, but not with energy intake(29,30). Moreover, the addition
of dairy products and fatty fish (both high in protein) to a
macrobiotic diet had a marked positive effect on linear
growth in these children(29,31).
The mechanism linking dietary protein to linear growth is
not well understood. Insulin is increased after ingestion of cer-
tain amino acids and carbohydrates(32,33), which could lead to
a rise in IGF-1 concentration, although a previous study did
not detect differences in GH or IGF-1 responses after ingestion
of different mixtures of protein and/or carbohydrates(33). Min-
erals, such as Zn and Ca, of which the intake is usually
increased in individuals with a high protein intake, may also
be associated with IGF-1; however, these results are also con-
troversial(34–36). Arginine is thought to inhibit endogenous
somatostatin release, and consequently stimulate the release
Table 2. Descriptives of children participating in the present study and the complete database*
(Mean values and standard deviations or percentages)
Included children Complete database
n Mean SD n Mean SD
Background of parents
SES 1/2/3 (%)† 255 28/36/36 583 28/34/38
Height of mother (cm) 246 168·8 26·5 521 168·0 29·8
Height of father (cm) 246 182·2 35·9 494 182·8 40·8
Baseline
Sex Boys/Girls (%) 261 47/53 787 51/49
Age (years) 261 6·8 0·3 698 6·8 0·4
Anthropometrics
Height (cm) 261 124·1 4·4 693 122·9 5·0
Weight (kg) 261 24·4 3·0 695 24·3 3·7
SES, socio-economic status of the mother.
* No differences between the descriptives of children participating in the present study and the complete database (P.0·73).
† SES: 1, #10 years elementary school; 2, high school or short non-university programmes under 3 years; 3, college or university degree over 3 years.
Table 3. Association of dietary arginine (mg/d) or dietary protein (excluding arginine) (g/d) and growth velocity (cm/year)
(b Coefficients and 95 % confidence intervals; n 261)
Quintiles
1 2 3 4 5
b 95 % CI b 95 % CI b 95 % CI b 95 % CI P for trend
Arginine as the main determinant
,2·2 g/d 2·2–2·5 g/d 2·5–2·8 g/d 2·8–3·2 g/d .3·2 g/d
Crude 0 0·13 0·21, 0·47 0·25 20·04, 0·45 0·29 20·08, 0·65 0·11 20·18, 0·40 0·34
Adjusted† 0 0·13 20·10, 0·37 0·26* 0·02, 0·50 0·33* 0·06, 0·60 0·05 20·25, 0·34 0·04
Adjusted‡ 0 0·11 20·19, 0·40 0·21 20·13, 0·54 0·27 20·16, 0·71 0·01 20·47, 0·50 0·21
Protein (excluding arginine)
as the main determinant
,58 g/d 58–65 g/d 65–72 g/d 72–79 g/d .79 g/d
Adjusted§ 0 0·14 20·10, 0·37 0·27* 0·01, 0·52 0·28 20·01, 0·56 0·11 20·23, 0·44 0·14
* Values were significantly different compared with an arginine intake ,2200 mg/d or protein intake ,58 g/d.
† Adjusted for sex, age, baseline height, puberty stages at follow-up 2, and group (intervention/control).
‡ Adjusted for sex, age, baseline height, mean energy intake (MJ/d), mean protein intake (excluding arginine) (g/d), puberty stages at follow-up 2, and group (intervention/con-
trol).
§ Adjusted for sex, age, baseline height, mean energy intake (MJ/d), puberty stages at follow-up 2, and group (intervention/control).
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of GH. Besides, it has been argued that NO, a metabolite of
arginine, may be involved in the inhibition of somatostatin
release(25). The present study could not confirm an involve-
ment of GH or IGF-1, as these measures were not available
for our cohort.
Furthermore, the following limitations should be kept in
mind when interpreting the results of the study. Measurement
error in estimating the amount of arginine intake in children
may have occurred despite dietary data having been carefully
collected by 7 d food records(37). Lillegaard et al.(38) found that
57 % of the participants were classified as acceptable reporters,
39 % as under-reporters and 4 % as over-reporters with the
precoded food diary. This suggests that energy intake in the
present study may have been under-reported. However,
other studies have shown that, although energy intake is fre-
quently under-reported, protein reporting is more accurate
and less influenced by errors than energy(39). While errors in
total protein may not be substantial, and even if the mean
intake of arginine from the present study corresponds well
with the mean intake of arginine in another Danish database
in children, it remains unknown whether this also applies
to the composition of the amino acids, the building blocks
of protein.
Besides, loss to follow-up was relatively high, especially in
the 7-year follow-up. This is probably due to the repeated
informed consent for the 7-year follow-up, which was not
included in the original research protocol of the study.
However, based on the similarity of baseline variables of the
children included in the final analysis and the complete set
of children (Table 2), we expect no bias due to loss to
follow-up.
The intake of protein and consequently arginine in
Western society is several-fold the physiological needs, and
there is a small variation in main protein sources. Therefore,
studies on dietary arginine could give stronger associations
with linear growth in the non-Western society, where intake
of protein is less and where there is more variation in main
protein sources (i.e. soya and vegetables). Experimental
studies are needed to investigate the specific role of arginine
on growth velocity compared with other amino acids.
Implications and future research
The aim of the present study was to gain knowledge about
physiological triggers, i.e. dietary interventions, as an alterna-
tive for GH therapy to stimulate linear growth. A meta-analysis
investigating the effect of GH therapy on height gain in chil-
dren with ISS showed an increase in height of approximately
4 cm during 5–7 years of GH therapy v. no treatment(1),
i.e. approximately 0·7 cm/year. In normally growing children,
we found a maximal growth velocity associated with dietary
arginine of 0·3 cm/year. This is approximately half of the
calculated effect of GH on growth velocity. Of note, in the pre-
sent study, we have not investigated the effect of arginine
intake on linear growth in children with a short stature, but
in normally growing children. The effect of arginine on
linear growth in children with a short stature will have to be
further investigated in future studies.
Conclusion
The present study is the first to show a dose–response
effect between dietary protein and, specifically, dietary argi-
nine, and growth velocity in normally growing children. The
present results suggest a dose-dependent physiological role
of habitual protein intake, and specifically arginine intake,
on linear growth in children. The present data indicate
that children with an arginine intake between 2·8 and
3·2 g/d grew 0·33 cm/year faster compared with children
with an arginine intake below 2·2 g/d. However, since the
study was designed in healthy children, we cannot firmly
conclude whether arginine supplementation represents a rel-
evant clinical strategy, and therefore further research will be
needed to investigate whether dietary protein and, in par-
ticular, dietary arginine may also represent a nutritional strat-
egy in the prevention and treatment of short stature. We
think such research would be especially valuable since argi-
nine as a dietary constituent is not only dramatically less
expensive than GH therapy, but also far more convenient
for children and their parents. One possible step could be
the initiation of observational studies on the relationship
of protein and arginine intake and growth in children with
a short stature.
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